Therapeutic methods involving gastrointestinal implants
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12409133-B2
Publication Date
2025-09-09
Expiration Date
Abstract
The present invention provides combination therapies for treating a metabolic disorder, such as type 2 diabetes, obesity, and related comorbidities (e.g., NASH or NAFLD)) in an individual undergoing treatment with a gastrointestinal implant. The combination therapies described herein include methods for treating an individual with a gastrointestinal implant with a metabolic agent, a bariatric procedure, and/or a microbiota modulator.
Core Innovation
The invention relates to a method of treating a metabolic disorder in an individual undergoing treatment with a gastrointestinal implant comprising an anchor and a sleeve. The method includes administering one or more metabolic agents in an amount and for a duration to treat the metabolic disorder.
The metabolic agents include incretin modulators such as GLP-1 receptor agonists and DPP-4 inhibitors. The metabolic agents are administered before or during implant treatment, and routes are described as enteral or parenteral.
The invention further describes combination approaches in which other interventions are coordinated with the gastrointestinal implant treatment. Bariatric procedures are described as restrictive bariatric procedures, including intragastric balloons and gastroplasty with transmural tissue anchor plications, and microbiota modulators include probiotics or microbial strains, fecal microbiota transplant, prebiotics, and bacteriophage.
Claims Coverage
The provided material includes one independent claim and one dependent claim. The independent claim has 1 inventive feature, and the dependent claim refines the timing of administering metabolic agents relative to gastrointestinal implant treatment.
Metabolic disorder treatment during gastrointestinal implant with anchor and sleeve
Administering one or more metabolic agents to an individual undergoing treatment with a gastrointestinal implant comprising an anchor and a sleeve, wherein the agents are given in an amount and for a duration to treat the metabolic disorder.
Timing of metabolic agent administration relative to implant treatment
Administering the one or more metabolic agents prior to treatment with the gastrointestinal implant or during treatment with the gastrointestinal implant.
Overall, the claim coverage centers on treating a metabolic disorder in an individual receiving a gastrointestinal implant with an anchor and sleeve by administering one or more metabolic agents in an amount and for a duration sufficient to treat the disorder, with timing specified as prior to or during implant treatment.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?